[en] BACKGROUND AND AIM: Hepatitis C virus genotype 2 is the third in order of frequency in Belgium. The aim of this study was to better define the genotype 2 carriers' epidemiology characteristics. METHODS: In a database comprising 1726 viremic hepatitis C virus patient from the south part of Belgium, the files of 98 genotype 2 carriers were reviewed. RESULTS: There was a strong association between genotype 2 and the mode of transmission. The rate of contamination by invasive medical exams was very high (23%), and statistically different from the one of the others genotypes. Eligibility for antiviral therapies and the rate of sustained viral response were high. CONCLUSION: HCV genotype 2 was highly associated with transmission by invasive medical exams.
Disciplines :
Surgery Gastroenterology & hepatology
Author, co-author :
Putzeys, V.
GERARD, Christiane ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
Bastens, B.
Wain, E.
Bataille, Christian ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Defrance, P.
Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
DE ROOVER, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation
DETRY, Olivier ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
Honoré, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie biologique et immuno hématologie
VAN DAMME P., VELLINGA A. Epidemiology of hepatitis B et C in Europe. Acta Gastroenterol Belg, 1998, 61: 175-182.
BEUTELS M., VAN DAMME P., AELVOET W. Prevalence of hepatitis A, B and C in the Flemish population. Eur J Epidemiol, 1997, 13: 275-280.
EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol, 1999, 30: 956-61.
FOSLER G., GOLDIN R., THOMAS H. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology, 1998, 27: 209-212.
SIMMONDS P., ALBERTI A., ALTER H.J. et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology, 1994, 19: 1321-4.
SMITH D., PATHIRANA S., DAVIDSON F. et al. The origin of hepatits C virus genotype J Gen Virol, 1997, 78: 321-328.
ZEIN N. Clinical significience of hepatits C virus genotype. Clin Microbiol Rev, 2000, 13: 223-235.
STRADER D., WRIGHT T., THOMAS D., SEEF L. Diagnosis, management and treatment of hepatitis C AASLD practice guideline. Hepatology, 2004, 39: 1147-1171.
PYBUS O., CHARLESTON M., GUPTA S., RAMBAUL A., HOLMES E., HARVEY P. The epidemic behavior of the hepatitis C Virus Science, 2001, 292: 2323-2325.
PAWLOTSKY JM., TSAKIRIS L., ROUDOT-THORAVAL F. et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J. Infect. Dis., 1995, 171: 1607-10.
MARTINOT-PEIGNOUX M., ROUDOT-THORAVAL F., MENDEL I. et al. Hepatitis C virus genotypes in France: relationship with epidemiology, patho genicity and response to interferon therapy. J. Viral Hepatitis, 1999, 6: 435-43.
DELWAIDE J., REENAERS C., GÉRARD C. et al. HCV Genotype 4 in Belgium: three distinct patterns among patient from European and African origin. Eur. J. Gastroenterol. Hepatol., 2006, 18: 707-712.
GERARD C., DELWAIDE J., VAIRA D. et al. Evolution over a 10 Year Period of the Epidemiological Profile of 1726 Newly Diagnosed HCV Patients in Belgium. J. Med. Virology, 2005, 76: 503-510.
DELWAIDE J., GERARD C., REENAERS C. et al. Hepatitis C virus genotype 5 in Southern Belgium: epidemiological characteristics and response to therapy. Digestive Diseases ans Sciences, 2005, 50: 2348-2351.
KLETER B., BROUWER J., NEVENS F. et al. Hepatitis C virus genotypes: epidemiological and clinical associations. Liver, 1998, 18: 32-38.
POYNARD T., MARCELLIN P., LEE S. et al. Randomised trial of interferon alpha 2b plus ribavirine for 48 weeks or for 24 weeks versus inerferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet, 1998, 342: 1426-1432.
DELWAIDE J., EL SAOUDA R., GERARD C. et al. Hepatitis C infection: eligibility for antiviral therapies. Eur. J. Gastroenterol. and Hepatology, 2005, 17: 1185-1189.
POL S., ROMEO R., ZINS B. et al. Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications. Kidney Int., 1993, 44: 1097-100.
SIMON N., COUROUCE A.M., LEMARREC N., TRÉPO C., DUCAMPS S. A twelve year natural history of hepatitis C virus infection in hemodialyzed patients. Kidney Int., 1994, 46: 504-11.
WENZEL R., EDMOND M. Patient-to-patient transmission of hepatitis C virus. Ann. Intern. Med., 2005, 142: 940-941.
DELWAIDE J., BOURGEOIS N., GERARD C. et al. Treatment of acute hepatitic C with interferon alpha-2b: early initiation is effective predictive factor of sustained viral response. Aliment Pharmacol. Ther., 2004, 20: 15-22.
DELWAIDE J., GERARD C., VAIRA D. et al. Hepatitis C virus transmission following invasive medical procedures. J. Intern. Med., 1999, 245: 107-8.
MACEDO DE OLIVEIRA A., WHITE K., LESCHINSKY D. et al. An outbreak of hepatitis C virus infections among outpatients at a haematology/oncology clinic. Ann. Intern. Med., 2005, 142: 898-902.
LAGGING L., ANEMAN C., NENONEN N. et al. Nosocomial transmission of HCV in a cardiology Ward during de window phase of infection: an epidemiological and molecular investigation. Scand. J. Infect. Dis., 2002, 34: 580-582.
SILINI E., LOCASCIULLI A., SANTOLERI L. et al. Hepatitis C infection in a haematology Ward: evidence for nosocomial transmission and impact on haematology disease outcome. Haematologica, 2002, 87: 1200-1208.
KRAUSE G., TREPKA M., WHISENHUNT R. et al. Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. Infect. Control Hosp. Epidemiol., 2003, 24: 122-127.
FURYOSO N., KUBO N., NAKASHIMA H. et al. Confirmation of nosocomial hepatitis C virus infection in a haemodialysis unit. Infect. Control Hosp. Epidemiol., 2004, 25: 584-590.
MASSARI M., PETROSILLO N., IPPOLITO G. et al. Transmission of hepatitis C virus in a gynaecological surgery setting. J. Clin. Microbiol., 2001, 39: 2860-2863.
DE LEDINGHEN V., TRIMOULET P., MANNANT P.R. et al. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow up of, 196 patients (4535 patient-years). J. Hepatol., 2007, 46: 19-25.
DE LEDINGHEN V., TRIMOULET P., CAZAJOUS G. et al. Epidemio-logical and phylogenetic evidence for patient-to-patient hepatitis C virus transmission during sclerotherapy of varicose veins. J. Med. Virol., 2005, 76: 279-284.
DELTENRE P. Virological tools for optimal management of chronic hepatitis C. Acta Gastroenterol. Belg., 2009, 72: 421-4.
